Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales.
Fourth-quarter worldwide sales increased 7% year-over-year to $15.6 billion, with Pharmaceutical and Animal Health revenues growing 7% and 9% respectively.
The company reported a net profit of $3.74 billion or $1.48 per share for the December quarter, compared to a loss of $1.23 billion or $0.48 per share in the prior-year period. On an adjusted basis, earnings climbed to $1.72 per share in Q4 from $0.03 per share in the fourth quarter of 2023.
“Our business remains well-positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential,” said Merck’s CEO Robert Davis.
The post MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]